Featured Story
Featured
CHMP Recommends Pembrolizumab and Chemo for Pleural Mesothelioma
Amna Anees
4 mins read - November 17, 2024
By suggesting pembrolizumab (Keytruda) in conjunction with chemotherapy as a first-line treatment for patients with malignant pleural mesothelioma, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has made a major advancement in the fight against mesothelioma. This proposal represents a...
News & Data
Amna Anees - September 23, 2024
FDA Approves Pembrolizumab with Chemotherapy for Advanced Mesothelioma
Rachel Sasser - September 20, 2024
J&J Subsidiary Declares Bankruptcy to Push Forward $10 Billion Talc Settlement
Rachel Sasser - September 18, 2024
$39M Awarded In Mesothelioma Case Tied to Medical Contaminated Talc
Matthew Davis - September 11, 2024
Is J&J Playing Fair? Lawyers Dispute the $1.1 Billion Talc Settlement Increase
Mesowatch serves as an industry watchdog and advocates for patients and families affected by asbestos by providing reliable and up-to-date news stories and information on asbestos and mesothelioma.
CONTACT US
Email: support@mesowatch.com
Phone: (866) 402-1000
Address: 3260 N Hayden Rd, Suite 210, Scottsdale, AZ 85251
Copyright © 2024 by Mesowatch. All Rights Reserved.
At Mesowatch, we strive to provide helpful information for your journey. Please remember that the content on our website is for informational purposes only and is protected by copyright law. It is not a substitute for professional medical or legal advice. We encourage you to consult qualified professionals for any health or legal concerns. Disclaimer